Sun Pharma Faces US Generic Pressure Despite Specialty Growth

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Sun Pharma Faces US Generic Pressure Despite Specialty Growth
Overview

Sun Pharma's latest results show growth in specialty medicines and emerging markets, but US generic drug prices continue to decline. The company plans to acquire Organon for $11.8 billion, a move that shifts its strategy toward global expansion financed by debt, raising concerns about execution and short-term profit margins.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Mixed Performance in a Challenging US Market

Sun Pharmaceutical Industries started the new fiscal year with a mixed operational picture. The company reported a 26% year-on-year increase in its consolidated net profit for the quarter, reaching ₹2,714 crore. However, the market's response was muted, underscoring ongoing concerns about its strategy in the United States. Innovative medicine sales now represent over 22% of Sun Pharma's total revenue, a positive trend. Yet, earnings before interest, taxes, depreciation, and amortization (EBITDA) margins are under pressure. Higher marketing expenses and a reduced contribution from Revlimid sales have offset gains from specialty drugs. The company's stock is currently trading at a price-to-earnings (P/E) multiple of about 38x, suggesting investors expect a smooth growth transition. This valuation comes despite a 1.1% drop in US formulation sales measured in dollars.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.